HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Arbutus Biopharma (NASDAQ:ABUS) and maintains a $6 price target.
June 22, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Arbutus Biopharma and maintains a $6 price target.
The reiterated Buy rating and maintained $6 price target by HC Wainwright & Co. analyst Ed Arce indicates a positive outlook for Arbutus Biopharma. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100